About sphingotec
sphingotec develops diagnostic methods for the prediction and diagnosis of diseases in the fields of cancer, cardiovascular and renal diseases. For this purpose, sphingotec investigates biomarkers that identify the individual predisposition to serious diseases in order to enable improved prevention and/or early treatment measures. In addition, sphingotec develops biomarkers for the early diagnosis of severe acute diseases (e.g. renal function/dysfunction, shock), which can be used to support the stratification of patients for treatment and the monitoring of therapeutic curative measures. Founded in 2002 by Dr. Andreas Bergmann, the company is located northwest of Berlin in the Technologiecampus Hennigsdorf, one of the largest industrial parks in the Berlin-Brandenburg region, home to numerous companies from the biotechnology sector.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Focus : Manufacturer
- Industry : Diagnostics
